

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jacobson Pharma Corporation Limited

雅各臣科研製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Stock Code : 2633

POSITIVE PROFIT ALERT

This announcement is made by Jacobson Pharma Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Directors**”) of the Company (the “**Board**”) wishes to inform shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2022 and the information currently available to the Board, the Group expects to record an increase of around 70% in the consolidated profit attributable to equity shareholders of the Company for the six months ended 30 September 2022 as compared to that for the six months ended 30 September 2021.

The increase was attributable to the easing off of social distancing measures which facilitated the resumption of medical consultation visits in both public and private sectors in Hong Kong, thus boosting the demand for essential drugs as well as specialty medicines for chronic diseases. This uplifted sales demand, together with an improvement in sale prices, product mix and operating leverage, coupled with the subsidies from the Hong Kong Government pertinent to the Employment Support Scheme, resulted in a notable increase in profit for the six months ended 30 September 2022. The trend of aging population, along with a high prevalence of chronic disease in Hong Kong, will continue to support the growth momentum and are expected to benefit the Group’s business in the foreseeable future. Buttressed by a vertically-integrated supply chain, alongside its robust production and product development capabilities, the Group will continue to drive its growth strategies to fortify its market position whilst vigorously pursuing its strategic roadmap.

As at the date of this announcement, the consolidated results of the Group for the six months ended 30 September 2022 have not yet been finalised. The information contained in this announcement is only based on a preliminary assessment by the Board with reference to unaudited consolidated management accounts of the Group for the six months ended 30 September 2022 and the information currently available to the Board. Such information has not been reviewed and confirmed by the auditor of the Company, and may be subject to adjustments. Further details of the Group's performance will be disclosed in the interim results announcement of the Company for the six months ended 30 September 2022 in accordance with the Listing Rules, which is expected to be published on 25 November 2022.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jacobson Pharma Corporation Limited
YU Chun Kau
Company Secretary

Hong Kong, 2 November 2022

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Wong Chi Kei, Ian as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Lam Sing Kwong, Simon as independent non-executive Directors.